Bonou Maria, Mavrogeni Sophie, Kapelios Chris J, Skouloudi Marina, Aggeli Constantina, Cholongitas Evangelos, Papatheodoridis George, Barbetseas John
Department of Cardiology, Laiko General Hospital, 11527 Athens, Greece.
Department of Cardiology, Onassis Cardiac Surgery Center, 17674 Athens, Greece.
Diagnostics (Basel). 2021 Jan 5;11(1):75. doi: 10.3390/diagnostics11010075.
Cardiovascular (CV) complications represent the first non-graft-related cause of death and the third overall cause of death among patients undergoing liver transplantation (LT). History of coronary artery disease is related to increased CV mortality following LT. Although it is of paramount importance to stratify CV risk in pre-LT patients, there is no consensus regarding the choice of the optimal non-invasive cardiac imaging test. Algorithms proposed by scientific associations include non-traditional risk factors, which are associated with increased cardiac risk profiles. Thus, an individualized pre-LT evaluation protocol should be followed. As the average age of patients undergoing LT and the number of candidates continue to rise, the "3 W" questions still remain unanswered, Who, Which and When? Who should be screened for coronary artery disease (CAD), which screening modality should be used and when should the asymptomatic waitlisted patients repeat cardiac evaluation? Prospective studies with large sample sizes are warranted to define an algorithm that can provide better risk stratification and more reliable survival prediction.
心血管(CV)并发症是肝移植(LT)患者非移植相关的首要死亡原因和总体第三大死亡原因。冠心病史与LT后CV死亡率增加有关。尽管在LT术前患者中对CV风险进行分层至关重要,但对于最佳非侵入性心脏成像检查的选择尚无共识。科学协会提出的算法包括与增加的心脏风险特征相关的非传统风险因素。因此,应遵循个体化的LT术前评估方案。随着接受LT患者的平均年龄和候选人数持续上升,“3W”问题仍然没有答案,即谁、哪种方法和何时?谁应该接受冠状动脉疾病(CAD)筛查,应该使用哪种筛查方式,以及无症状的等待名单上的患者何时应重复心脏评估?有必要进行大样本量的前瞻性研究,以确定一种能够提供更好的风险分层和更可靠生存预测的算法。